Avidity Biosciences, INC Form 4 insider transactions

Director Arthur Levin exercised stock options and sold shares of Avidity Biosciences (RNA) on September 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

W. Michael Flanagan, CSTO of Avidity Biosciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, exercised stock options and sold 25,000 shares of common stock at an average price of $40.4017, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Director Arthur A. Levin reports gifting shares of Avidity Biosciences stock to family and charitable remainder trusts.

Director Arthur Levin exercised stock options and sold shares of Avidity Biosciences (RNA) on August 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares on August 6, 2024, according to a Form 4 filing with the SEC.

John B. Moriarty, Chief Legal Officer of Avidity Biosciences, acquired 25,000 shares of common stock and stock options for 160,000 shares on August 1, 2024, as reported in a Form 4 filing with the SEC.

Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences under a pre-arranged Rule 10b5-1 trading plan.

Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, sold shares to cover tax obligations following the vesting of performance-based restricted stock units (PSUs) due to the initiation of the Phase 3 HARBOR trial for del-desiran.

Chief Financial Officer Michael F. MacLean of Avidity Biosciences reports acquisition and disposal of common stock related to performance-based restricted stock units (PSUs) vesting upon achievement of a Phase 3 trial milestone.

Avidity Biosciences CEO Sarah Boyce reports acquisition and disposal of company stock related to the vesting of performance-based restricted stock units (PSUs) and subsequent sell-to-cover transactions.

W. Michael Flanagan, CSTO of Avidity Biosciences, sold shares to cover tax obligations following the vesting of performance-based restricted stock units (PSUs) due to the initiation of the Phase 3 HARBOR trial for del-desiran.

Director Edward M. Kaye acquired stock options in Avidity Biosciences on June 13, 2024.

Avidity Biosciences' CFO, Michael F. MacLean, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Director Jean Jinsun Kim reports acquisition of stock options in Avidity Biosciences.

Director Arthur Levin sold shares of Avidity Biosciences (RNA) on June 12 and 13, 2024, according to a Form 4 filing with the SEC.

Director Carsten Boess acquired stock options in Avidity Biosciences, Inc. on June 13, 2024.

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares of common stock between June 12 and June 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Tamar Thompson acquired stock options in Avidity Biosciences, Inc. on June 13, 2024.

Director Noreen Henig reports the acquisition of stock options in Avidity Biosciences.

Director Troy Edward Wilson acquired stock options in Avidity Biosciences, Inc. on June 13, 2024.

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares on June 4, 2024, according to a Form 4 filing with the SEC.

Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences, Inc. on May 20, 2024, according to a Form 4 filing with the SEC.

Avidity Biosciences' CFO, Michael F. MacLean, exercised stock options and sold 75,000 shares of common stock on May 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Simona Skerjanec received stock options for 42,308 shares of Avidity Biosciences (RNA) on May 14, 2024.

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares on May 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Arthur A. Levin exercised stock options and sold 5,000 shares of Avidity Biosciences (RNA) common stock on April 19, 2024, according to a Form 4 filing with the SEC.

Director Arthur Levin sold 20,000 shares of Avidity Biosciences (RNA) at an average price of $27.1107 on April 3, 2024.